Literature DB >> 16357167

Novel role for PDEF in epithelial cell migration and invasion.

Ruwanthi N Gunawardane1, Dennis C Sgroi, Carolyn N Wrobel, Eugene Koh, George Q Daley, Joan S Brugge.   

Abstract

Cell migration and invasion are two critical cellular processes that are often deregulated during tumorigenesis. To identify factors that contribute to oncogenic progression by stimulating cell migration, we conducted a powerful retroviral based migration screen using an MCF7 cDNA library and the immortalized human breast epithelial cell line MCF-10A. We identified prostate derived Ets factor (PDEF), an Ets transcription factor that is overexpressed in both prostate and breast carcinoma, as a candidate promigratory gene from this screen. Whereas PDEF induced limited motility of MCF-10A cells, coexpression of PDEF with the receptor tyrosine kinases (RTK) ErbB2 and colony-stimulating factor receptor (CSF-1R)/CSF-1 significantly enhanced MCF-10A motility. Furthermore, cells coexpressing PDEF with either ErbB2 or CSF-1R/CSF-1 induced a dramatic invasive phenotype in three-dimensional cultures. Constitutive activation of the extracellular signal-regulated kinase (ERK) pathway also enhanced PDEF-induced motility and invasion, suggesting that activation of the ERK/mitogen-activated protein kinase by ErbB2 and CSF-1R/CSF-1 can cooperate with PDEF to promote motility and invasion. Furthermore, PDEF promoted anchorage-independent growth of ErbB2 and CSF-1R/CSF-1-expressing cells. Using laser capture microdissection, we also found that PDEF mRNA is overexpressed in breast tumor epithelia throughout tumor progression. Taken together, these findings suggest that the transcription factor PDEF may play an important role in breast tumorigenesis and that PDEF overexpression may be particularly significant in tumors that exhibit activation of oncogenic RTKs such as ErbB2 and CSF-1R.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357167      PMCID: PMC2919290          DOI: 10.1158/0008-5472.CAN-05-1196

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

Review 1.  Ets target genes: past, present and future.

Authors:  V I Sementchenko; D K Watson
Journal:  Oncogene       Date:  2000-12-18       Impact factor: 9.867

2.  Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer.

Authors:  Paul N Span; Peggy Manders; Joop J Heuvel; Chris M G Thomas; Remko R Bosch; Louk V A M Beex; C G J Sweep
Journal:  Oncogene       Date:  2002-12-05       Impact factor: 9.867

3.  Novel retroviral vectors to facilitate expression screens in mammalian cells.

Authors:  Eugene Y Koh; Tong Chen; George Q Daley
Journal:  Nucleic Acids Res       Date:  2002-12-15       Impact factor: 16.971

4.  The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer.

Authors:  P Behrens; M Rothe; A Wellmann; J Krischler; N Wernert
Journal:  J Pathol       Date:  2001-05       Impact factor: 7.996

5.  PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression.

Authors:  P Oettgen; E Finger; Z Sun; Y Akbarali; U Thamrongsak; J Boltax; F Grall; A Dube; A Weiss; L Brown; G Quinn; K Kas; G Endress; C Kunsch; T A Libermann
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

6.  Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen.

Authors:  A Ghadersohi; A K Sood
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

7.  An ERK2 docking site in the Pointed domain distinguishes a subset of ETS transcription factors.

Authors:  Jeffrey J Seidel; Barbara J Graves
Journal:  Genes Dev       Date:  2002-01-01       Impact factor: 11.361

8.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini.

Authors:  S K Muthuswamy; D Li; S Lelievre; M J Bissell; J S Brugge
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

9.  A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice.

Authors:  N Neznanov; A K Man; H Yamamoto; C A Hauser; R D Cardiff; R G Oshima
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

10.  Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes.

Authors:  M Mitas; K Mikhitarian; L Hoover; M A Lockett; L Kelley; A Hill; W E Gillanders; D J Cole
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

View more
  39 in total

1.  ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells.

Authors:  Keneshia K Haenssen; Sarah A Caldwell; Kristina S Shahriari; S Raelle Jackson; Kelly A Whelan; Andres J Klein-Szanto; Mauricio J Reginato
Journal:  J Cell Sci       Date:  2010-03-23       Impact factor: 5.285

2.  Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis.

Authors:  Tobias Schmelzle; Arnaud A Mailleux; Michael Overholtzer; Jason S Carroll; Nicole L Solimini; Eric S Lightcap; Ole P Veiby; Joan S Brugge
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-26       Impact factor: 11.205

3.  The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

Authors:  Paraic A Kenny; Genee Y Lee; Connie A Myers; Richard M Neve; Jeremy R Semeiks; Paul T Spellman; Katrin Lorenz; Eva H Lee; Mary Helen Barcellos-Hoff; Ole W Petersen; Joe W Gray; Mina J Bissell
Journal:  Mol Oncol       Date:  2007-06       Impact factor: 6.603

4.  Sustained PKCβII activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner.

Authors:  Mohamad El Osta; Mengling Liu; Mohamad Adada; Can E Senkal; Jolanta Idkowiak-Baldys; Lina M Obeid; Christopher J Clarke; Yusuf A Hannun
Journal:  FASEB J       Date:  2013-10-11       Impact factor: 5.191

Review 5.  Making sense of cancer genomic data.

Authors:  Lynda Chin; William C Hahn; Gad Getz; Matthew Meyerson
Journal:  Genes Dev       Date:  2011-03-15       Impact factor: 11.361

6.  Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer.

Authors:  Ali Ghadersohi; Satish Sharma; Shaozeng Zhang; Rami G Azrak; Gregory E Wilding; Masoud H Manjili; Fengzhi Li
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

Review 7.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

8.  Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.

Authors:  Ali Ghadersohi; Kunle Odunsi; Shaozeng Zhang; Rami G Azrak; Brian N Bundy; Masoud H Manjili; Fengzhi Li
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

9.  ETS-4 is a transcriptional regulator of life span in Caenorhabditis elegans.

Authors:  Bargavi Thyagarajan; Adam G Blaszczak; Katherine J Chandler; Jennifer L Watts; W Evan Johnson; Barbara J Graves
Journal:  PLoS Genet       Date:  2010-09-16       Impact factor: 5.917

10.  Profiling Y561-dependent and -independent substrates of CSF-1R in epithelial cells.

Authors:  Melodie L Knowlton; Laura M Selfors; Carolyn N Wrobel; Ting-Lei Gu; Bryan A Ballif; Steven P Gygi; Roberto Polakiewicz; Joan S Brugge
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.